Merck KGaA buys rights to Oncothyreon's lung cancer vaccine

12/18/2008 | Seattle Times, The

Oncothyreon sold manufacturing rights to Stimuvax, its investigational lung cancer vaccine, to Merck KGaA for $13 million. The deal is part of a restructuring that seeks "to create a sustainable team intensely focused on our clinical-development activities," Oncothyreon CEO Robert Kirkman said.

View Full Article in:

Seattle Times, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC